Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...

NLS Pharmaceutics (NLSP) announces new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...

Further enabling AI innovation for the life sciences industry, Veeva Systems today announced that Direct Data API is now included for no additional license fee as part of Veeva Vault Platform. Veeva ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced record-breaking financial results for 2024, driven by robust ...

When you’re hungry after learning something, your brain might prioritize remembering some kinds of information over others. A ...

Alkermes plc. (NASDAQ: ALKS )财务副总裁兼临时首席会计官Samuel Joseph Parisi于2025年2月28日出售了1,938股公司股票。每股售价为34.00美元，总计交易额为65,892美元。此次交易是根据Parisi于2024年9月11日采用的Rule ...

近日，市值57亿美元、股价接近52周高点36.45美元的制药公司Alkermes plc. (NASDAQ: ALKS )的财务副总裁兼临时首席会计官Samuel Joseph Parisi于2025年2月25日出售了3,743股普通股。每股平均售价为35.26美元，总计约13.2万美元。此次出售是根据Parisi于2024年9月11日采用的Rule 10b5-1交易计划进行的。根据 ...

Depression refers to a state of low mood that can be accompanied with loss of interest in activities that the individual normally perceived as pleasurable, altered appetite and sleep/wake balance ...